Journal: Molecular imaging and biology

Article Title: An analysis of isoclonal antibody formats suggests a role for measuring PD-L1 with low molecular weight PET radiotracers

doi: 10.1007/s11307-020-01527-3

Figure Lengend Snippet: A summary of the kinetic constants for the C4 minibody, scFv and their respective DFO-conjugates. The binding was assayed against the ectodomain of recombinant human PD-L1 using biolayer interferometry. The data are representative of two independent experiments. In the case of the K D and the K dis for the C4 minibody, the constants approached the limit of detection and the instrument was not capable of reporting error calculations.

Article Snippet: Kinetic constants for the minibody and scFv antibody against human and mouse PD-L1 (Sino Biological Inc.) were determined via biolayer interferometry with an Octet RED384 instrument (ForteBio) using a previously described approach[ 11 ].

Techniques: Binding Assay, Recombinant

Journal: Molecular imaging and biology

Article Title: An analysis of isoclonal antibody formats suggests a role for measuring PD-L1 with low molecular weight PET radiotracers

doi: 10.1007/s11307-020-01527-3

Figure Lengend Snippet: A. At left is shown a plot of the blood and tumor activity values for the radiolabeled C4 minibody at several time points after its injection into immunocompetent mice bearing implanted B16F10 tumor cells. Tumor uptake was statistically higher than blood starting from 1.5 hours post injection. Tumor uptake peaked at 1.5 hours and declined from 1.5 to 2.5 hours, which mirrors the behavior we observed with the 89Zr-C4 minibody or IgG1 over a longer window of time. At right are shown transaxial CT and PET/CT taken at 1.5 hours post injection. The tumor is on the left hindlimb. B. At left is shown a plot of the blood and tumor activity values for the radiolabeled C4 scFv at several time points after its injection into nu/nu mice bearing H1975 xenografts. Tumor uptake was statistically higher than blood starting from 0.5 hours post injection. At right are shown transaxial CT and PET/CT taken at 1.5 hours post injection. The tumor is on the left hindlimb. C. Biodistribution data from select normal tissues from C57Bl6/J mice. D. Biodistribution data from select normal tissues from nu/nu mice.

Article Snippet: Kinetic constants for the minibody and scFv antibody against human and mouse PD-L1 (Sino Biological Inc.) were determined via biolayer interferometry with an Octet RED384 instrument (ForteBio) using a previously described approach[ 11 ].

Techniques: Activity Assay, Injection, Positron Emission Tomography-Computed Tomography

Journal: Molecular imaging and biology

Article Title: An analysis of isoclonal antibody formats suggests a role for measuring PD-L1 with low molecular weight PET radiotracers

doi: 10.1007/s11307-020-01527-3

Figure Lengend Snippet: A. DAR and anti-PDL1 immunohistochemistry (co-stained with hematoxylin) of a liver section from a 1 year old female Alb Cre; MYCTg; KRASG12D genetically engineered mouse model of heptacellular carcinoma. Multiple tracer avid foci are detected against the background of normal liver. At right are shown the merged images with the PDL1 immunohistochemistry magnified at 40X in selected fields of view to show the concordance between radiotracer binding and PD-L1 expression in tumor. Additional fields of view and tumor slices are shown in Supplemental Figure 1. B. Biodistribution data showing the uptake of 89Zr-scFv in an orthotopic hepatocellular tumor established from a mouse cell line derived from the Alb Cre; MYCTg; KRASG12D GEM model.

Article Snippet: Kinetic constants for the minibody and scFv antibody against human and mouse PD-L1 (Sino Biological Inc.) were determined via biolayer interferometry with an Octet RED384 instrument (ForteBio) using a previously described approach[ 11 ].

Techniques: Immunohistochemistry, Staining, Binding Assay, Expressing, Derivative Assay

Journal: Microbiome

Article Title: Tumor-colonized Streptococcus mutans metabolically reprograms tumor microenvironment and promotes oral squamous cell carcinoma.

doi: 10.1186/s40168-024-01907-9

Figure Lengend Snippet: Fig. 5 Single-cell transcriptomic landscape reveals the shift of the cellular types during oral carcinogenesis, and KYNA is a predominant driving force for expansions and infiltrations of neutrophils in the TME of OSCC. A Overview of the workflow for scRNA-seq analyses of OLK and OSCC rat tongue tissues. B UMAP plot of the clustering results for 13 major cell types from OLK and OSCC tissues. C Stacked histogram of the percentages of different cells from OLK and OSCC tissues. D Quantitative analysis of neutrophils, macrophages, and T cells in non-epithelial cells in OLK and OSCC tissues. E H&E and IHC staining for CD11b in OLK and OSCC tissues of experimental rats. Scale bar: 600 µm for 4 × magnification and 300 µm for 10 × magnification. F Representative IHC staining images and statistical analysis of CD16 in saline and KYNA-treated 4NQO rats. Scale bars: 200 µm for 10 × magnification and 50 µm for 40 × magnification. G Representative flow cytometry dot plots and statistical analysis of CD11b + CD16 + neutrophils from the peripheral blood of OSCC patients after KYNA treatment. H Relative SLC7A8 expression in neutrophils from OSCC patients after KYNA treatment detected by RT-qPCR. I Representative flow cytometry dot plots and statistical analysis of AHR + neutrophils from OSCC patients after treatments with KYNA in indicated concentrations. In D, unpaired Student’s t-test; E and F, Mann– Whitney U test; G, H, and I, one-way ANOVA

Article Snippet: At week 20, the rats were sacrificed, and the tongues were dissected, and a longitudinal mid-lingual incision was made. (4) IL-1β/PD-L1monoclonal antibody (mAb) intervention (8 rats/group): (A) 4NQO + IL-1β mAb (200 μg/rat, BE0246, cloneB122, Bioxcell, USA); (B) 4NQO + KYNA + IL-1β mAb; (C) 4NQO + PD-L1 mAb (200 μg/rat, BE0383, clone 368A.4H1, Bioxcell, USA); (D) 4NQO + KYNA + PD-L1 mAb; (E) 4NQO + control IgG (200 μg/rat, BE0091, Bioxcell, USA).

Techniques: Immunohistochemistry, Saline, Flow Cytometry, Expressing, Quantitative RT-PCR, MANN-WHITNEY

Journal: Leukemia

Article Title: Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents

doi: 10.1038/leu.2013.355

Figure Lengend Snippet: (A) Increased mRNA expression of PD-L1, PD-L2, PD-1 and CTLA4 genes in CD34+ cells from MDS, CMML and AML patients by real-time PCR analysis, normal CD34+ cells were used as normal control. N = number of patients. MDS, myelodysplastic syndromes; CMML, chronic myelomonocytic leukemia; AML, acute myeloid leukemia. (B) Increased mRNA expression of PD-L1, PD-L2, PD-1 and CTLA4 in PBMNCs from MDS, CMML and AML patients, normal PBMNCs were used as normal controls. PBMNC, peripheral blood mononuclear cells. (C) Comparisons of mRNA expression levels of PD-L1, PD-L2, PD-1 and CTLA4 between CD34+ cells and PBMNC from MDS, CMML and AML patients.

Article Snippet: APC mouse anti-human PD-1 and PE mouse anti-human PD-L1 antibodies were obtained from BD Biosciences (San Jose, CA).

Techniques: Expressing, Real-time Polymerase Chain Reaction

Journal: Leukemia

Article Title: Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents

doi: 10.1038/leu.2013.355

Figure Lengend Snippet: (A) Illustrations of PD-L1 membranous expression in bone marrow biopsy samples from MDS, CMML and AML patients (X1000): a, Representative case show strong PD-L1 membranous expression in blasts; b, Representative case show negative PD-L1 membranous expression in blasts. (B) Illustrations of PD-1 membranous expression in bone marrow biopsy samples from MDS, CMML and AML patients (X1000): a, Representative case show PD-1 membranous expression in blasts; b, Representative case show negative PD-1 membranous expression in blasts, but positive PD-1 expression in stroma/non-blast compartment. (C) Illustrations of PD-L1 membranous expression in CD34+ cell cytospin from MDS, CMML and AML patients (X1000): a, Representative case show strong PD-L1 membranous expression; b, Representative case show negative PD-L1 membranous expression. (D) Illustrations of PD-1 membranous expression in CD34+ cell cytospin from MDS, CMML and AML patients (X1000): a, Representative case show partial PD-1 membranous expression; b, Representative case show negative PD-1 membranous expression.

Article Snippet: APC mouse anti-human PD-1 and PE mouse anti-human PD-L1 antibodies were obtained from BD Biosciences (San Jose, CA).

Techniques: Expressing

Journal: Leukemia

Article Title: Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents

doi: 10.1038/leu.2013.355

Figure Lengend Snippet: (A) Summary of dynamics of PD-L1, PD-L2, PD-1 and CTLA4 mRNA expression in 61 patients treated with different forms of epigenetic therapy, expression on day 0 was baseline expression before treatment, most patients received 5 days of hypomethylating agent treatment. (B) Induction of PD-L1, PD-L2, PD-1 and CTLA4 expression in patients treated in a phase 2 trial of vorinostat in combination with azacitidine. C=course, D=days on therapy. Resistance: patients had no response to treatment; Responing: patients acquired complete remission after treatment. (C) Overall survival by comparison of PD-L2 upregulation after treatment in group of patients from a phase 2 trial of vorinostat in combination with azacitidine. Group 0: group of patients without PD-L2 expression induction (≥2 fold) after theatment; Group 1: group of patients acquired PD-L2 expression induction (≥2 fold) after theatment.

Article Snippet: APC mouse anti-human PD-1 and PE mouse anti-human PD-L1 antibodies were obtained from BD Biosciences (San Jose, CA).

Techniques: Expressing

Journal: Leukemia

Article Title: Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents

doi: 10.1038/leu.2013.355

Figure Lengend Snippet: (A) Induction of PD-L1, PD-1 and CTLA4 mRNA expression in KG-1 treated with different concentrations of decitabine and cytarabine. (B) Induction of PD-L1 and PD-L2 mRNA expression in THP1 treated with different concentrations of decitabine and cytarabine. (C) Flow cytometry analysis of PD-1 and PD-L1 protein expression levels in KG-1 treated with different concentrations of decitabine.

Article Snippet: APC mouse anti-human PD-1 and PE mouse anti-human PD-L1 antibodies were obtained from BD Biosciences (San Jose, CA).

Techniques: Expressing, Flow Cytometry

Journal: Leukemia

Article Title: Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents

doi: 10.1038/leu.2013.355

Figure Lengend Snippet: (A) PD-1 methylation in leukemia cell lines, AML patients and normal controls. (B) Dynamics of PD-1 methylation in KG-1 leukemia cell line treated with decitabine by pyrosequencing analysis, N=Number. (C) Bisulfite sequencing analysis of dynamics of PD-1 methylation with decitabine treatment of KG-1. (D) Dynamics of PD-1 methylation in AML and MDS patients from group of patients treated with vorinostat in combination with azacitidine, C=Course; D=days on therapy.

Article Snippet: APC mouse anti-human PD-1 and PE mouse anti-human PD-L1 antibodies were obtained from BD Biosciences (San Jose, CA).

Techniques: Methylation, Methylation Sequencing